Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617.

ABSTRACT:

Background

Lutetium-177-prostate-specific membrane antigen- 617 (Lu-PSMA) is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC). However, treatment responses are heterogeneous despite stringent positron emission tomography (PET)-based imaging selection criteria. Molecularly based biomarkers have potential to refine patient selection and optimise outcomes.

Objective

To identify circulating tumour DNA (ctDNA) features associated with treatment outcomes for men treated with Lu-PSMA.

Design setting and participants

ctDNA from men treated with Lu-PSMA in combination with idronoxil for progressive mCRPC were analysed using an 85-gene customised sequencing assay. ctDNA fractions, molecular profiles, and the presence of alterations in aggressive-

SUBMITTER: Crumbaker M 

PROVIDER: S-EPMC10658415 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature